Next Article in Journal
Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancer—A Promising Signaling Network for Therapeutic Interventions
Previous Article in Journal
Environmental Carcinogens and Cancer Risk
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436

1
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2
State Key Laboratory of Oncology in South China and Collaborative Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
3
Department of Molecular and Cellular Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4
Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA
5
Oncoceutics Inc., Philadelphia, PA 19104, USA
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(4), 623; https://doi.org/10.3390/cancers13040623
Submission received: 9 December 2020 / Accepted: 24 December 2020 / Published: 4 February 2021
In the original article, there was a mistake in Figure 2B as published [1]. Two images from the same mouse with different luminescence signals were presented.
When we image mice, we usually do it twice at different exposure time to make sure we capture any luminescence signals. All the mouse images presented in the manuscript, and the values of luminescence signals used for quantification, are from the same exposure time. However, the two mouse images highlighted in the PBS group in Figure 2B were indeed from the same mouse that were captured at different exposure times. That is why the luminescence signals of the two are different. That is a manual error when processing a large number of images. The authors have double-checked all of them and replaced the panel with a correct image. Another mistake is also fixed with one other image being swapped between the PBS and ONC201 groups. Nevertheless, these did not affect the quantification in Figure 2C, as the calculation was from values generated from the imaging software, which is independent to the process of putting the images together manually.
The corrected Figure 2B appears below:
Cancers 13 00623 i001
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. All the authors have checked and agreed with the corrected paper content. The original article has been updated.

Reference

  1. Hu, W.; Zhang, L.; Ferri-Borgogno, S.; Kwan, S.-Y.; Lewis, K.E.; Cun, H.T.; Yeung, T.-L.; Soliman, P.T.; Tarapore, R.S.; Allen, J.E.; et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hu, W.; Zhang, L.; Ferri-Borgogno, S.; Kwan, S.-Y.; Lewis, K.E.; Cun, H.T.; Yeung, T.-L.; Soliman, P.T.; Tarapore, R.S.; Allen, J.E.; et al. Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436. Cancers 2021, 13, 623. https://doi.org/10.3390/cancers13040623

AMA Style

Hu W, Zhang L, Ferri-Borgogno S, Kwan S-Y, Lewis KE, Cun HT, Yeung T-L, Soliman PT, Tarapore RS, Allen JE, et al. Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436. Cancers. 2021; 13(4):623. https://doi.org/10.3390/cancers13040623

Chicago/Turabian Style

Hu, Wen, Li Zhang, Sammy Ferri-Borgogno, Suet-Ying Kwan, Kelsey E. Lewis, Han T. Cun, Tsz-Lun Yeung, Pamela T. Soliman, Rohinton S. Tarapore, Joshua E. Allen, and et al. 2021. "Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436" Cancers 13, no. 4: 623. https://doi.org/10.3390/cancers13040623

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop